Document is current
Any future updates will be listed below
-
Authors
Arriaga, Juan M. https://orcid.org/0000-0001-7523-2955
Panja, Sukanya
Alshalalfa, Mohammed https://orcid.org/0000-0001-8405-3035
Zhao, Junfei
Zou, Min
Giacobbe, Arianna
Madubata, Chioma J.
Kim, Jaime Yeji
Rodriguez, Antonio
Coleman, Ilsa
Virk, Renu K.
Hibshoosh, Hanina
Ertunc, Onur https://orcid.org/0000-0002-4159-1711
Ozbek, Büşra
Fountain, Julia
Jeffrey Karnes, R.
Luo, Jun
Antonarakis, Emmanuel S.
Nelson, Peter S.
Feng, Felix Y. https://orcid.org/0000-0002-0963-7687
Rubin, Mark A. https://orcid.org/0000-0002-8321-9950
De Marzo, Angelo M.
Rabadan, Raul https://orcid.org/0000-0001-7946-9255
Sims, Peter A.
Mitrofanova, Antonina https://orcid.org/0000-0003-0671-6512
Abate-Shen, Cory https://orcid.org/0000-0002-5021-0570
- License Information
-
More Information
Article History
Received: 26 January 2020
Accepted: 10 September 2020
First Online: 19 October 2020
Competing interests
: A.M.D. has sponsored research funding from Janssen R&D and consults for Cepheid. R.J.K. receives Royalties from GenomeDx. E.S.A. has served as a paid consultant/advisor to Janssen, Pfizer, Sanofi, Dendreon, Bayer, Bristol Myers Squibb, Amgen, Merck, AstraZeneca and Clovis; has received research grants to his institution from Janssen, Johnson&Johnson, Sanofi, Bristol Myers Squibb, Pfizer, AstraZeneca, Celgene, Merck, Bayer and Clovis; and is an inventor of a biomarker technology that has been licensed to QIAGEN. All other authors declare no competing interests.
